List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1780396/publications.pdf Version: 2024-02-01

		16451	6471
305	27,847	64	157
papers	citations	h-index	g-index
312	312	312	18649
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Estimation of cardiac output variations induced by hemodynamic interventions using multi-beat analysis of arterial waveform: a comparative off-line study with transesophageal Doppler method during non-cardiac surgery. Journal of Clinical Monitoring and Computing, 2022, 36, 501-510.	1.6	3
2	Characteristics and prognosis of Herpesviridae-related pneumonia in critically ill burn patients. Burns, 2022, 48, 1155-1165.	1.9	4
3	Immunity and inflammation: the neglected key players in congenital heart disease?. Heart Failure Reviews, 2022, 27, 1957-1971.	3.9	22
4	Acute Heart Failure in the 2021 ESC Heart Failure Guidelines: a scientific statement from the Association for Acute CardioVascular Care (ACVC)Âof the European Society of Cardiology. European Heart Journal: Acute Cardiovascular Care, 2022, 11, 173-185.	1.0	31
5	Inotropes and vasopressors are associated with increased short-term mortality but not long-term survival in critically ill patients. Anaesthesia, Critical Care & Pain Medicine, 2022, 41, 101012.	1.4	7
6	Usefulness of lactate albumin ratio at admission to predict 28-day mortality in critically ill severely burned patients: A retrospective cohort study. Burns, 2022, 48, 1836-1844.	1.9	2
7	A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction–Âinsights from the <scp>ESCâ€HFA EORP</scp> Heart Failure Longâ€Term Registry. European Journal of Heart Failure, 2022, 24, 335-350.	7.1	49
8	Clinical Characteristics and Predictors of In-Hospital Mortality among Older Patients with Acute Heart Failure. Journal of Clinical Medicine, 2022, 11, 439.	2.4	5
9	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2022, 24, 4-131.	7.1	820
10	High plasma dipeptidyl peptidase 3 levels are associated with mortality and organ failure in shock: results from the international, prospective and observational FROG-ICU cohort. British Journal of Anaesthesia, 2022, 128, e54-e57.	3.4	10
11	Which dose of ketamine to use for rapid sequence intubation in critically ill patients in hemodynamic shock?. Journal of Clinical Anesthesia, 2022, 78, 110675.	1.6	2
12	Anesthetic drugs for rapid sequence intubation: ketamine, but what dose?. Intensive Care Medicine, 2022, 48, 632-633.	8.2	3
13	Single-dose of adrecizumab versus placebo in acute cardiogenic shock (ACCOST-HH): an investigator-initiated, randomised, double-blinded, placebo-controlled, multicentre trial. Lancet Respiratory Medicine,the, 2022, 10, 247-254.	10.7	12
14	Biologically Active Adrenomedullin (bio-ADM) is of Potential Value in Identifying Congestion and Selecting Patients for Neurohormonal Blockade in Acute Dyspnea. American Journal of Medicine, 2022, 135, e165-e181.	1.5	1
15	A case-control, multicentre study of consecutive patients with COVID-19 and acute (myo)pericarditis: incidence, risk factors, clinical characteristics and outcomes. Emergency Medicine Journal, 2022, 39, 402-410.	1.0	5
16	Early echocardiography by treating physicians and outcome in the critically ill: An ancillary study from the prospective multicenter trial FROG-ICU. Journal of Critical Care, 2022, 69, 154013.	2.2	4
17	The association of biological sex and long-term outcomes in patients with acute dyspnea at the emergency department. European Journal of Emergency Medicine, 2022, 29, 195-203.	1.1	3
18	Identifying clinical subtypes in sepsis-survivors with different one-year outcomes: a secondary latent class analysis of the FROG-ICU cohort. Critical Care, 2022, 26, 114.	5.8	12

#	Article	IF	CITATIONS
19	GuÃa ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica. Revista Espanola De Cardiologia, 2022, 75, 523.e1-523.e114.	1.2	40
20	Acetazolamide in Decompensated Heart Failure with Volume Overload trial (<scp>ADVOR</scp>): baseline characteristics. European Journal of Heart Failure, 2022, 24, 1601-1610.	7.1	18
21	Real-time estimation of mean arterial blood pressure based on photoplethysmography dicrotic notch and perfusion index. A pilot study. Journal of Clinical Monitoring and Computing, 2021, 35, 395-404.	1.6	8
22	Alteration of the Renin–Angiotensin–Aldosterone System in Shock: Role of the Dipeptidyl Peptidase 3. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 526-527.	5.6	11
23	Impact of Coronavirus Disease 2019 (COVID-19) Outbreak on Acute Admissions at the Emergency and Cardiology Departments Across Europe. American Journal of Medicine, 2021, 134, 482-489.	1.5	53
24	Drug development in oncology and devices—lessons for heart failure drug development and approval? a review. Heart Failure Reviews, 2021, 26, 255-262.	3.9	0
25	Performance of a multiplex polymerase chain reaction panel for identifying bacterial pathogens causing pneumonia in critically ill patients with COVID-19. Diagnostic Microbiology and Infectious Disease, 2021, 99, 115183.	1.8	31
26	Increased anticoagulation reduces proximal deep vein thrombosis in mechanically ventilated COVID-19 patients. Journal of Infection, 2021, 82, 186-230.	3.3	8
27	Adrecizumab: an investigational agent for the biomarker-guided treatment of sepsis. Expert Opinion on Investigational Drugs, 2021, 30, 95-102.	4.1	8
28	Vascular endothelial growth factor D is a biomarker of fluid overload in haemodialysis patients. Nephrology Dialysis Transplantation, 2021, 36, 529-536.	0.7	5
29	Current use of inotropes in circulatory shock. Annals of Intensive Care, 2021, 11, 21.	4.6	35
30	Monitoring circulating dipeptidyl peptidase 3 (DPP3) predicts improvement of organ failure and survival in sepsis: a prospective observational multinational study. Critical Care, 2021, 25, 61.	5.8	25
31	Acute heart failure treatment: a light at the end of the tunnel?. European Journal of Heart Failure, 2021, 23, 698-702.	7.1	5
32	Predictive value of plasma proenkephalin and neutrophil gelatinase-associated lipocalin in acute kidney injury and mortality in cardiogenic shock. Annals of Intensive Care, 2021, 11, 25.	4.6	13
33	Role of Damage-Associated Molecular Patterns in Septic Acute Kidney Injury, From Injury to Recovery. Frontiers in Immunology, 2021, 12, 606622.	4.8	22
34	Temporal trends in mortality and readmission after acute heart failure: a systematic review and metaâ€regression in the past four decades. European Journal of Heart Failure, 2021, 23, 420-431.	7.1	67
35	The Impact of Patients With CardiacÂAmyloidosis in HFpEF Trials. JACC: Heart Failure, 2021, 9, 169-178.	4.1	39
36	Medical Therapy of Heart Failure with Reduced Ejection Fraction—A Call for Comparative Research. Journal of Clinical Medicine, 2021, 10, 1803.	2.4	1

#	Article	IF	CITATIONS
37	The <scp>CLIP</scp> â€based mortality score in cardiogenic shock: suitable only for cardiogenic shock?. European Journal of Heart Failure, 2021, 23, 1240-1242.	7.1	2
38	Urinary peptides in heart failure: a link to molecular pathophysiology. European Journal of Heart Failure, 2021, 23, 1875-1887.	7.1	37
39	Comparison of Circulating Immune Cells Profiles and Kinetics Between Coronavirus Disease 2019 and Bacterial Sepsis*. Critical Care Medicine, 2021, 49, 1717-1725.	0.9	11
40	Pulmonary embolism in patients with COVID-19: incidence, risk factors, clinical characteristics, and outcome. European Heart Journal, 2021, 42, 3127-3142.	2.2	90
41	A urinary peptidomic profile predicts outcome in SARS-CoV-2-infected patients. EClinicalMedicine, 2021, 36, 100883.	7.1	28
42	Readmission following both cardiac and non ardiac acute dyspnoea is associated with a striking risk of death. ESC Heart Failure, 2021, 8, 2473-2484.	3.1	5
43	Rapid identification of bacteria from respiratory samples of patients hospitalized in intensive care units, with FilmArray Pneumonia Panel Plus. International Journal of Infectious Diseases, 2021, 108, 568-573.	3.3	9
44	Impact of Midregional Nâ€Terminal Pro–Atrial Natriuretic Peptide and Soluble Suppression of Tumorigenicity 2 Levels on Heart Rhythm in Patients Treated With Catheter Ablation for Atrial Fibrillation: The Biorhythm Study. Journal of the American Heart Association, 2021, 10, e020917.	3.7	6
45	Effectiveness of anaesthesia ventilator use for mechanical ventilation in critically ill patients during the COVID-19 pandemic. British Journal of Anaesthesia, 2021, 127, e35-e37.	3.4	1
46	Outcomes of patients with heart failure with preserved ejection fraction discharged on treatment with neurohormonal antagonists after an episode of decompensation. European Journal of Internal Medicine, 2021, 94, 73-84.	2.2	5
47	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2021, 42, 3599-3726.	2.2	5,558
48	Early intravenous nitroglycerin use in prehospital setting and in the emergency department to treat patients with acute heart failure: Insights from the EAHFE Spanish registry. International Journal of Cardiology, 2021, 344, 127-134.	1.7	5
49	Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (<scp>HFA</scp>), European Society of Cardiology (<scp>ESC</scp>). European Journal of Heart Failure, 2021, 23, 1610-1632.	7.1	69
50	Elevated Plasma Bioactive Adrenomedullin and Mortality in Cardiogenic Shock: Results from the OptimaCC Trial. Journal of Clinical Medicine, 2021, 10, 4512.	2.4	2
51	Amended <scp>STRONGâ€HF</scp> study design. European Journal of Heart Failure, 2021, 23, 1981-1982.	7.1	8
52	Optimising clinical trials in acute myocardial infarction complicated by cardiogenic shock: a statement from the 2020 Critical Care Clinical Trialists Workshop. Lancet Respiratory Medicine,the, 2021, 9, 1192-1202.	10.7	28
53	Regional variation of effects of new antidiabetic medications in cardiovascular outcome trials. American Heart Journal, 2021, 240, 73-80.	2.7	1
54	The FAST-FURO study: effect of very early administration of intravenous furosemide in the prehospital setting to patients with acute heart failure attending the emergency department. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 487-496.	1.0	3

#	Article	IF	CITATIONS
55	How to manage a woman presenting with acute PPCM?. , 2021, , 33-43.		2
56	Safety and tolerability of non-neutralizing adrenomedullin antibody adrecizumab (HAM8101) in septic shock patients: the AdrenOSS-2 phase 2a biomarker-guided trial. Intensive Care Medicine, 2021, 47, 1284-1294.	8.2	40
57	Design and Rationale of the National Tunisian Registry of Heart Failure (NATURE-HF): Protocol for a Multicenter Registry Study. JMIR Research Protocols, 2021, 10, e12262.	1.0	3
58	Effects of levosimendan on occurrence of cerebral vasospasm after aneurysmal subarachnoid hemorrhage: a case–control study. Critical Care, 2021, 25, 396.	5.8	5
59	Single-dose tocilizumab blunts systemic inflammation in severe COVID-19 patients. Journal of Critical Care, 2021, , .	2.2	Ο
60	Time-pattern of adverse outcomes after an infection-triggered acute heart failure decompensation and the influence of early antibiotic administration and hospitalisation: results of the PAPRICA-3 study. Clinical Research in Cardiology, 2020, 109, 34-45.	3.3	8
61	Early hypoalbuminemia is associated with 28-day mortality in severely burned patients: A retrospective cohort study. Burns, 2020, 46, 630-638.	1.9	6
62	Circulating dipeptidyl peptidase 3 is a myocardial depressant factor: dipeptidyl peptidase 3 inhibition rapidly and sustainably improves haemodynamics. European Journal of Heart Failure, 2020, 22, 290-299.	7.1	55
63	Unmet medical needs, resources allocation and issues regarding cost-effectiveness in critical care. Anaesthesia, Critical Care & Pain Medicine, 2020, 39, 111-112.	1.4	2
64	Characteristics and outcomes of HFpEF with declining ejection fraction. Clinical Research in Cardiology, 2020, 109, 225-234.	3.3	20
65	One-year outcome of patients admitted after cardiac arrest compared to other causes of ICU admission. An ancillary analysis of the observational prospective and multicentric FROG-ICU study. Resuscitation, 2020, 146, 237-246.	3.0	3
66	Circulating dipeptidyl peptidase 3 and alteration in haemodynamics in cardiogenic shock: results from the OptimaCC trial. European Journal of Heart Failure, 2020, 22, 279-286.	7.1	53
67	Imaging in patients with suspected acute heart failure: timeline approach position statement on behalf of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 181-195.	7.1	47
68	What Is the Role of Medical Therapy in Cardiogenic Shock in the Era of Mechanical Circulatory Support?. Canadian Journal of Cardiology, 2020, 36, 151-153.	1.7	5
69	Serum Lactate and A Relative Change in Lactate as Predictors of Mortality in Patients With Cardiogenic Shock – Results from the Cardshock Study. Shock, 2020, 53, 43-49.	2.1	15
70	Impact of hypotension on cerebral perfusion during general anesthesia induction: A prospective observational study in adults. Acta Anaesthesiologica Scandinavica, 2020, 64, 592-601.	1.6	10
71	Protein S100B as a reliable tool for early prognostication after cardiac arrest. Resuscitation, 2020, 156, 251-259.	3.0	9
72	Effect of an Emergency Department Care Bundle on 30-Day Hospital Discharge and Survival Among Elderly Patients With Acute Heart Failure. JAMA - Journal of the American Medical Association, 2020, 324, 1948.	7.4	52

#	Article	IF	CITATIONS
73	A Time-Dependent Propensity Score Matching Approach to Assess Epinephrine Use on Patients Survival Within Out-of-Hospital Cardiac Arrest Care. Journal of Emergency Medicine, 2020, 59, 542-552.	0.7	2
74	Sex differences in circulating proteins in heart failure with preserved ejection fraction. Biology of Sex Differences, 2020, 11, 47.	4.1	12
75	Inhibition of circulating dipeptidyl-peptidase 3 restores cardiac function in a sepsis-induced model in rats: A proof of concept study. PLoS ONE, 2020, 15, e0238039.	2.5	26
76	Influence of noninvasive central blood pressure devices for afterload monitoring with aortic velocity-pressure Loop in anesthetized patients. Blood Pressure Monitoring, 2020, 25, 184-194.	0.8	1
77	Designing an ARDS trial for 2020 and beyond: focus on enrichment strategies. Intensive Care Medicine, 2020, 46, 2153-2156.	8.2	31
78	The heart failure specialists of tomorrow: a network for young cardiovascular scientists and clinicians. ESC Heart Failure, 2020, 7, 873-877.	3.1	2
79	Monitoring of cardiovascular physiology augmented by a patient-specific biomechanical model during general anesthesia. A proof of concept study. PLoS ONE, 2020, 15, e0232830.	2.5	15
80	Heart rate as an independent predictor of long term mortality of acute heart failure patients in sinus rhythm according to their ejection fraction: data from the AHEAD registry. European Journal of Internal Medicine, 2020, 78, 88-94.	2.2	2
81	Epidemiology, pathophysiology and contemporary management of cardiogenic shock–Âa position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 1315-1341.	7.1	244
82	Activation of the renin-angiotensin-aldosterone system is associated with Acute Kidney Injury in COVID-19. Anaesthesia, Critical Care & Pain Medicine, 2020, 39, 453-455.	1.4	32
83	Accuracy of a multiparametric score based on pulse wave analysis for prediction of fluid responsiveness: ancillary analysis of an observational study. Canadian Journal of Anaesthesia, 2020, 67, 1162-1169.	1.6	1
84	Incidence and Outcome of Subclinical Acute Kidney Injury Using penKid in Critically Ill Patients. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 822-829.	5.6	31
85	The association of long-term outcome and biological sex in patients with acute heart failure from different geographic regions. European Heart Journal, 2020, 41, 1357-1364.	2.2	47
86	Added value of serial bio-adrenomedullin measurement in addition to lactate for the prognosis of septic patients admitted to ICU. Critical Care, 2020, 24, 69.	5.8	5
87	Acute heart failure. Nature Reviews Disease Primers, 2020, 6, 16.	30.5	237
88	Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use. Journal of Cardiovascular Pharmacology, 2020, 76, 4-22.	1.9	49
89	Response to beta-blockers and natriuretic peptide level in acute heart failure: analysis of data from the Korean acute heart failure registry. Clinical Research in Cardiology, 2020, 110, 1392-1403.	3.3	1
90	Physiological response to fluid resuscitation with Ringer lactate versus Plasmalyte in critically ill burn patients. Journal of Applied Physiology, 2020, 128, 709-714.	2.5	11

#	Article	IF	CITATIONS
91	Enhanced clinical phenotyping by mechanistic bioprofiling in heart failure with preserved ejection fraction: insights from the MEDIA-DHF study (The Metabolic Road to Diastolic Heart Failure). Biomarkers, 2020, 25, 201-211.	1.9	26
92	Contemporary strategies to improve clinical trial design for critical care research: insights from the First Critical Care Clinical Trialists Workshop. Intensive Care Medicine, 2020, 46, 930-942.	8.2	49
93	Hemodynamic response of restoring sinus rhythm in critically ill patients with atrial fibrillation. American Journal of Emergency Medicine, 2020, 38, 1192-1194.	1.6	1
94	PenKid measurement at admission is associated with outcome in severely ill burn patients. Burns, 2020, 46, 1302-1309.	1.9	4
95	Acute coronary syndromes and acute heart failure: a diagnostic dilemma and highâ€risk combination. A statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 1298-1314.	7.1	50
96	Improved cardiac and venous pressures during hospital stay in patients with acute heart failure: an echocardiography and biomarkers study. ESC Heart Failure, 2020, 7, 996-1006.	3.1	10
97	Megaâ€trials in heart failure: effects of dilution in examination of new therapies. European Journal of Heart Failure, 2020, 22, 1698-1707.	7.1	11
98	Circulating dipeptidyl peptidase-3 at admission is associated with circulatory failure, acute kidney injury and death in severely ill burn patients. Critical Care, 2020, 24, 168.	5.8	22
99	Assessment of successful percutaneous mitral commissurotomy by MRproANP and sCD146. BMC Cardiovascular Disorders, 2020, 20, 157.	1.7	3
100	Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use. Cardiac Failure Review, 2020, 6, e19.	3.0	37
101	Management of Acute Heart Failure during an Early Phase. International Journal of Heart Failure, 2020, 2, 91.	2.7	9
102	Patient with Severe Right Heart Failure and Preserved Left Ventricular Ejection Function. , 2020, , 249-261.		0
103	Microcirculatory Dysfunction in Acute Heart Failure. , 2020, , 193-221.		2
104	Title is missing!. , 2020, 15, e0232830.		0
105	Title is missing!. , 2020, 15, e0232830.		0
106	Title is missing!. , 2020, 15, e0232830.		0
107	Title is missing!. , 2020, 15, e0232830.		0

#	ARTICLE	IF	CITATIONS
109	Title is missing!. , 2020, 15, e0238039.		0
110	Title is missing!. , 2020, 15, e0238039.		0
111	Title is missing!. , 2020, 15, e0238039.		0
112	Safety, Tolerability and efficacy of Rapid Optimization, helped by NTâ€proBNP and GDFâ€15, of Heart Failure therapies (STRONGâ€HF): rationale and design for a multicentre, randomized, parallelâ€group study. European Journal of Heart Failure, 2019, 21, 1459-1467.	7.1	34
113	Evolution of B-type natriuretic peptide and N-terminal pro-brain natriuretic peptide during acute decompensated heart failure in a chronic heart failure patient with reduced ejection fraction treated with Sacubitril/Valsartan: aÂcase report. European Heart Journal - Case Reports, 2019, 3, ytz108.	0.6	1
114	Editor's Choice– Impact of identifying precipitating factors on 30-day mortality in acute heart failure patients. European Heart Journal: Acute Cardiovascular Care, 2019, 8, 667-680.	1.0	15
115	Gender and survival of critically ill patients: results from the FROG-ICU study. Annals of Intensive Care, 2019, 9, 43.	4.6	32
116	Short-Term Therapies for Treatment of Acute and Advanced Heart Failure—Why so Few Drugs Available in Clinical Use, Why Even Fewer in the Pipeline?. Journal of Clinical Medicine, 2019, 8, 1834.	2.4	14
117	Acute Kidney Injury Induces Remote Cardiac Damage and Dysfunction Through the Galectin-3 Pathway. JACC Basic To Translational Science, 2019, 4, 717-732.	4.1	41
118	Adrecizumab, a non-neutralizing anti-adrenomedullin antibody, improves haemodynamics and attenuates myocardial oxidative stress in septic rats. Intensive Care Medicine Experimental, 2019, 7, 25.	1.9	25
119	Influence of the length of hospitalisation in post-discharge outcomes in patients with acute heart failure: Results of the LOHRCA study. European Journal of Internal Medicine, 2019, 70, 24-32.	2.2	7
120	CORT-AHF Study. JACC: Heart Failure, 2019, 7, 834-845.	4.1	12
121	A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure: An expert panel consensus. International Journal of Cardiology, 2019, 297, 83-90.	1.7	42
122	Comparison of echocardiographic indices of right ventricular systolic function and ejection fraction obtained with continuous thermodilution in critically ill patients. Critical Care, 2019, 23, 312.	5.8	12
123	Clinical phenotypes of acute heart failure based on signs and symptoms of perfusion and congestion at emergency department presentation and their relationship with patient management and outcomes. European Journal of Heart Failure, 2019, 21, 1353-1365.	7.1	56
124	Protein-based cardiogenic shock patient classifier. European Heart Journal, 2019, 40, 2684-2694.	2.2	30
125	Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. European Journal of Heart Failure, 2019, 21, 715-731.	7.1	446
126	Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. European Journal of Heart Failure, 2019, 21, 827-843.	7.1	223

#	Article	IF	CITATIONS
127	EEG power spectral density under Propofol and its association with burst suppression, a marker of cerebral fragility. Clinical Neurophysiology, 2019, 130, 1311-1319.	1.5	14
128	Contributing factors and outcomes of burn-associated cholestasis. Journal of Hepatology, 2019, 71, 563-572.	3.7	20
129	Ethnic differences in acute heart failure outcomes in Ontario. International Journal of Cardiology, 2019, 291, 177-182.	1.7	9
130	Influence of systemic hemodynamics on microcirculation during sepsis. Journal of Critical Care, 2019, 52, 213-218.	2.2	9
131	Plasma bio-adrenomedullin is a marker of acute heart failure severity in patients with acute coronary syndrome. IJC Heart and Vasculature, 2019, 22, 174-176.	1.1	12
132	Current use of vasopressors in septic shock. Annals of Intensive Care, 2019, 9, 20.	4.6	109
133	Impact of renin-angiotensin system inhibitors continuation versus discontinuation on outcome after major surgery: protocol of a multicenter randomized, controlled trial (STOP-or-NOT trial). Trials, 2019, 20, 160.	1.6	22
134	Noninvasive continuous detection of arterial hypotension during induction of anaesthesia using a photoplethysmographic signal: proof of concept. British Journal of Anaesthesia, 2019, 122, 605-612.	3.4	19
135	Propofol/Remifentanil Anesthesia Might Not Alter the Middle Cerebral Artery Diameter by Digital Subtraction Angiography. Neurocritical Care, 2019, 31, 338-345.	2.4	1
136	The continuous heart failure spectrum: moving beyond an ejection fraction classification. European Heart Journal, 2019, 40, 2155-2163.	2.2	195
137	Early and comprehensive care bundle in the elderly for acute heart failure in the emergency department: study protocol of the ELISABETH stepped-wedge cluster randomized trial. Trials, 2019, 20, 95.	1.6	4
138	A double-blind, placebo-controlled, randomised, multicentre, proof-of-concept and dose-finding phase Il clinical trial to investigate the safety, tolerability and efficacy of adrecizumab in patients with septic shock and elevated adrenomedullin concentration (AdrenOSS-2). BMJ Open, 2019, 9, e024475.	1.9	37
139	Current treatment and unmet needs of hyperkalaemia in the emergency department. European Heart Journal Supplements, 2019, 21, A12-A19.	0.1	28
140	Prolonged corrected QT interval is associated with short-term and long-term mortality in critically ill patients: results from the FROG-ICU study. Intensive Care Medicine, 2019, 45, 746-748.	8.2	8
141	One-Year Prognosis of Kidney Injury at Discharge From the ICU: A Multicenter Observational Study. Critical Care Medicine, 2019, 47, e953-e961.	0.9	21
142	Low compliance to guidelines in the management of acute heart failure in emergency elderly patients: a multicenter pilot prospective study. European Journal of Emergency Medicine, 2019, 26, 379-380.	1.1	4
143	Adrenomedullin in heart failure: pathophysiology and therapeutic application. European Journal of Heart Failure, 2019, 21, 163-171.	7.1	144
144	The use of diuretics in heart failure with congestion — a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21, 137-155.	7.1	605

#	Article	IF	CITATIONS
145	Incidence, risk factors and outcome of multi-drug resistant Acinetobacter baumannii nosocomial infections during an outbreak in a burn unit. International Journal of Infectious Diseases, 2019, 79, 179-184.	3.3	36
146	Evaluation of cardiac output variations with the peripheral pulse pressure to mean arterial pressure ratio. Journal of Clinical Monitoring and Computing, 2019, 33, 581-587.	1.6	3
147	Outcome and potentially modifiable risk factors for candidemia in critically ill burns patients: A matched cohort study. Mycoses, 2019, 62, 237-246.	4.0	13
148	Impact of an Acinetobacter baumannii outbreak on kidney events in a burn unit: A targeted machine learning analysis. American Journal of Infection Control, 2019, 47, 435-438.	2.3	9
149	Treatments targeting inotropy. European Heart Journal, 2019, 40, 3626-3644.	2.2	123
150	Risk Factors for Acute Mesenteric Ischemia in Critically Ill Burns Patients—A Matched Case–Control Study. Shock, 2019, 51, 153-160.	2.1	17
151	World Heart Federation Roadmap for Heart Failure. Global Heart, 2019, 14, 197.	2.3	67
152	Incidence, Risk Factors and Prognosis of Contrast-Induced Acute Kidney Injury in Acute Heart Failure Patients Undergoing Coronary Angiography. International Journal of Heart Failure, 2019, 1, 72.	2.7	2
153	Finding the balance between costs and quality in heart failure: a global challenge. European Journal of Heart Failure, 2018, 20, 1175-1178.	7.1	6
154	Beyond left ventricular ejection fraction there is a right heart that pumps: reply. European Journal of Heart Failure, 2018, 20, 1076-1077.	7.1	0
155	Evolution of natriuretic peptide biomarkers in heart failure: Implications for clinical care and clinical trials. International Journal of Cardiology, 2018, 254, 215-221.	1.7	19
156	A Right Insight in Cardiogenic Shock to Get It Right. Journal of Cardiac Failure, 2018, 24, 157-158.	1.7	2
157	East Asia may have a better 1â€year survival following an acute heart failure episode compared with Europe: results from an international observational cohort. European Journal of Heart Failure, 2018, 20, 1071-1075.	7.1	13
158	Acute Heart Failure Deserves a Log-ScaleÂBoost in Research Support. JACC: Heart Failure, 2018, 6, 76-79.	4.1	11
159	Increased dose of diuretics correlates with severity of heart failure and renal dysfunction and does not lead to reduction of mortality and rehospitalizations due to acute decompensation of heart failure; data from AHEAD registry. Cor Et Vasa, 2018, 60, e215-e223.	0.1	4
160	Acutely decompensated heart failure with preserved and reduced ejection fraction present with comparable haemodynamic congestion. European Journal of Heart Failure, 2018, 20, 738-747.	7.1	109
161	Indications and practical approach to non-invasive ventilation in acute heart failure. European Heart Journal, 2018, 39, 17-25.	2.2	111
162	The heart regulates the endocrine response to heart failure: cardiac contribution to circulating neprilysin. European Heart Journal, 2018, 39, 1794-1798.	2.2	27

#	Article	IF	CITATIONS
163	Comprehensive inâ€hospital monitoring in acute heart failure: applications for clinical practice and future directions for research. A statement from the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Journal of Heart Failure, 2018, 20, 1081-1099.	7.1	57
164	QSOX1, a novel actor of cardiac protection upon acute stress in mice. Journal of Molecular and Cellular Cardiology, 2018, 119, 75-86.	1.9	29
165	Sevoflurane for procedural sedation in critically ill patients: A pharmacokinetic comparative study between burn and non-burn patients. Anaesthesia, Critical Care & Pain Medicine, 2018, 37, 551-556.	1.4	14
166	Effects on short term outcome of non-invasive ventilation use in the emergency department to treat patients with acute heart failure: A propensity score-based analysis of the EAHFE Registry. European Journal of Internal Medicine, 2018, 53, 45-51.	2.2	11
167	Beat-by-beat assessment of cardiac afterload using descending aortic velocity–pressure loop during general anesthesia: a pilot study. Journal of Clinical Monitoring and Computing, 2018, 32, 23-32.	1.6	14
168	The BRONCHâ€AHF study: effects on shortâ€ŧerm outcome of nebulized bronchodilators in emergency department patients diagnosed with acute heart failure. European Journal of Heart Failure, 2018, 20, 822-826.	7.1	4
169	Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 16-37.	7.1	239
170	Association between hypo- and hyperkalemia and outcome in acute heart failure patients: the role of medications. Clinical Research in Cardiology, 2018, 107, 214-221.	3.3	28
171	Longâ€ŧerm safety of intravenous cardiovascular agents in acute heart failure: results from the European Society of Cardiology Heart Failure Longâ€Term Registry. European Journal of Heart Failure, 2018, 20, 332-341.	7.1	69
172	Acute kidney injury in cardiogenic shock: definitions, incidence, haemodynamic alterations, and mortality. European Journal of Heart Failure, 2018, 20, 572-581.	7.1	68
173	Heart failure oral therapies at discharge are associated with better outcome in acute heart failure: a propensityâ€score matched study. European Journal of Heart Failure, 2018, 20, 345-354.	7.1	92
174	Association of mineralocorticoid receptor antagonist use and in-hospital outcomes in patients with acute heart failure. Clinical Research in Cardiology, 2018, 107, 76-86.	3.3	15
175	Integrative Assessment of Congestion inÂHeart Failure Throughout the PatientÂJourney. JACC: Heart Failure, 2018, 6, 273-285.	4.1	152
176	Adjuvant therapy in acute heart failure. Intensive Care Medicine, 2018, 44, 900-903.	8.2	2
177	Addressing vulnerability: opening a new door to improved outcomes in acute heart failure. European Journal of Heart Failure, 2018, 20, 292-294.	7.1	2
178	Reply. Journal of the American College of Cardiology, 2018, 72, 2413.	2.8	1
179	Proenkephalin A 119-159 (Penkid) Is an Early Biomarker of Septic Acute Kidney Injury: The Kidney in Sepsis and Septic Shock (Kid-SSS) Study. Kidney International Reports, 2018, 3, 1424-1433.	0.8	53
180	Circulating adrenomedullin estimates survival and reversibility of organ failure in sepsis: the prospective observational multinational Adrenomedullin and Outcome in Sepsis and Septic Shock-1 (AdrenOSS-1) study. Critical Care, 2018, 22, 354.	5.8	75

#	Article	IF	CITATIONS
181	Use of levosimendan in acute heart failure. European Heart Journal Supplements, 2018, 20, I2-I10.	0.1	27

Rationale and design of the ADVOR (Acetazolamide in Decompensated Heart Failure with Volume) Tj ETQq000 rg $\beta_{.1}$ /Overlock 10 Tf 50

183	Improving Postdischarge Outcomes in Acute Heart Failure. American Journal of Therapeutics, 2018, 25, e475-e486.	0.9	17
184	Prediction of major adverse kidney events in critically ill burn patients. Burns, 2018, 44, 1887-1894.	1.9	10
185	Association of social deprivation with 1-year outcome of ICU survivors: results from the FROG-ICU study. Intensive Care Medicine, 2018, 44, 2025-2037.	8.2	28
186	Impact of angiotensin-converting enzyme inhibitors or receptor blockers on post-ICU discharge outcome in patients with acute kidney injury. Intensive Care Medicine, 2018, 44, 598-605.	8.2	62
187	Epinephrine and short-term survival in cardiogenic shock: an individual data meta-analysis of 2583 patients. Intensive Care Medicine, 2018, 44, 847-856.	8.2	106
188	Management of cardiogenic shock complicating myocardial infarction. Intensive Care Medicine, 2018, 44, 760-773.	8.2	126
189	Epinephrine Versus Norepinephrine forÂCardiogenic Shock After AcuteÂMyocardial Infarction. Journal of the American College of Cardiology, 2018, 72, 173-182.	2.8	282
190	Plasma neprilysin concentration during recovery from acute illness. European Heart Journal, 2018, 39, 3474-3475.	2.2	7
191	Biomarkers of increased intraventricular pressure: are we ready?. European Heart Journal Supplements, 2018, 20, G21-G27.	0.1	1
191 192	Biomarkers of increased intraventricular pressure: are we ready?. European Heart Journal Supplements, 2018, 20, G21-G27. Cardiovascular events after ICU discharge in patients with new-onset atrial fibrillation: A report from the FROG-ICU study. International Journal of Cardiology, 2018, 270, 203.	0.1	1
191 192 193	Biomarkers of increased intraventricular pressure: are we ready?. European Heart Journal Supplements, 2018, 20, G21-G27. Cardiovascular events after ICU discharge in patients with new-onset atrial fibrillation: A report from the FROG-ICU study. International Journal of Cardiology, 2018, 270, 203. Acute Heart Failure Management. Korean Circulation Journal, 2018, 48, 463.	0.1 1.7 1.9	1 1 16
191 192 193 194	Biomarkers of increased intraventricular pressure: are we ready?. European Heart Journal Supplements, 2018, 20, G21-G27. Cardiovascular events after ICU discharge in patients with new-onset atrial fibrillation: A report from the FROG-ICU study. International Journal of Cardiology, 2018, 270, 203. Acute Heart Failure Management. Korean Circulation Journal, 2018, 48, 463. Protracted immune disorders at one year after ICU discharge in patients with septic shock. Critical Care, 2018, 22, 42.	0.1 1.7 1.9 5.8	1 1 16 44
191 192 193 194	Biomarkers of increased intraventricular pressure: are we ready?. European Heart Journal Supplements, 2018, 20, G21-G27. Cardiovascular events after ICU discharge in patients with new-onset atrial fibrillation: A report from the FROG-ICU study. International Journal of Cardiology, 2018, 270, 203. Acute Heart Failure Management. Korean Circulation Journal, 2018, 48, 463. Protracted immune disorders at one year after ICU discharge in patients with septic shock. Critical Care, 2018, 22, 42. Determinants of long-term outcome in ICU survivors: results from the FROG-ICU study. Critical Care, 2018, 22, 8.	0.1 1.7 1.9 5.8 5.8	1 1 16 44 123
 191 192 193 194 195 196 	Biomarkers of increased intraventricular pressure: are we ready?. European Heart Journal Supplements, 2018, 20, C21-C27.Cardiovascular events after ICU discharge in patients with new-onset atrial fibrillation: A report from the FROG-ICU study. International Journal of Cardiology, 2018, 270, 203.Acute Heart Failure Management. Korean Circulation Journal, 2018, 48, 463.Protracted immune disorders at one year after ICU discharge in patients with septic shock. Critical Care, 2018, 22, 42.Determinants of long-term outcome in ICU survivors: results from the FROG-ICU study. Critical Care, 2018, 22, 8.Back-to-back comparison of penKID with NephroCheck® to predict acute kidney injury at admission in intensive care unit: a brief report. Critical Care, 2018, 22, 24.	0.1 1.7 1.9 5.8 5.8	1 1 16 44 123 20
 191 192 193 194 195 196 197 	Biomarkers of increased intraventricular pressure: are we ready?. European Heart Journal Supplements, 2018, 20, G21-G27. Cardiovascular events after ICU discharge in patients with new-onset atrial fibrillation: A report from the FROG-ICU study. International Journal of Cardiology, 2018, 270, 203. Acute Heart Failure Management. Korean Circulation Journal, 2018, 48, 463. Protracted immune disorders at one year after ICU discharge in patients with septic shock. Critical Care, 2018, 22, 42. Determinants of long-term outcome in ICU survivors: results from the FROG-ICU study. Critical Care, 2018, 22, 8. Back-to-back comparison of penKID with NephroCheck® to predict acute kidney injury at admission in intensive care unit: a brief report. Critical Care, 2018, 22, 24. VelocityâC ^{ee} pressure loops for continuous assessment of ventricular afterload: influence of pressure measurement site. Journal of Clinical Monitoring and Computing, 2018, 32, 833-840.	0.1 1.7 1.9 5.8 5.8 5.8 1.6	1 1 16 44 123 20 8

#	Article	IF	CITATIONS
199	Cardiorenal Interactions Revisited: How to Improve Heart Failure Outcomes in Patients With Chronic Kidney Disease. Current Heart Failure Reports, 2018, 15, 307-314.	3.3	12
200	Safety, tolerability and pharmacokinetics/pharmacodynamics of the adrenomedullin antibody adrecizumab in a firstâ€inâ€human study and during experimental human endotoxaemia in healthy subjects. British Journal of Clinical Pharmacology, 2018, 84, 2129-2141.	2.4	38
201	New-onset atrial fibrillation in critically ill patients and its association with mortality: A report from the FROG-ICU study. International Journal of Cardiology, 2018, 266, 95-99.	1.7	46
202	Agents with vasodilator properties in acute heart failure. European Heart Journal, 2017, 38, 317-325.	2.2	50
203	Adrenomedullin: a marker of impaired hemodynamics, organ dysfunction, and poor prognosis in cardiogenic shock. Annals of Intensive Care, 2017, 7, 6.	4.6	58
204	Estratificação prognóstica na hipertensão pulmonar: valor acrescido da abordagem multibiomarcadores. Revista Portuguesa De Cardiologia, 2017, 36, 111-125.	0.5	18
205	Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure. New England Journal of Medicine, 2017, 376, 1956-1964.	27.0	257
206	Morphine Use in the ED and Outcomes of Patients With Acute Heart Failure. Chest, 2017, 152, 821-832.	0.8	45
207	Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the <scp>ESC</scp> Heart Failure Longâ€Term Registry. European Journal of Heart Failure, 2017, 19, 1242-1254.	7.1	339
208	The relationship of circulating relaxinâ€2 concentrations with shortâ€ŧerm prognosis in patients with acute heart failure: the RELAHF study. European Journal of Heart Failure, 2017, 19, 1205-1209.	7.1	4
209	Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Journal of Heart Failure, 2017, 19, 821-836.	7.1	252
210	Combined Measurement of Soluble ST2 and Amino-Terminal Pro-B-Type Natriuretic Peptide Provides Early Assessment of Severity in Cardiogenic Shock Complicating Acute Coronary Syndrome. Critical Care Medicine, 2017, 45, e666-e673.	0.9	25
211	Acute heart failure with mid-range left ventricular ejection fraction: clinical profile, in-hospital management, and short-term outcome. Clinical Research in Cardiology, 2017, 106, 359-368.	3.3	57
212	IMPROV-ED study: outcomes after discharge for an episode of acute-decompensated heart failure and comparison between patients discharged from the emergency department and hospital wards. Clinical Research in Cardiology, 2017, 106, 369-378.	3.3	17
213	Soluble CD146 Is a Novel Marker of Systemic Congestion in Heart Failure Patients: An Experimental Mechanistic and Transcardiac Clinical Study. Clinical Chemistry, 2017, 63, 386-393.	3.2	34
214	Proenkephalin, Renal Dysfunction, andÂPrognosis in Patients With AcuteÂHeartÂFailure. Journal of the American College of Cardiology, 2017, 69, 56-69.	2.8	66
215	The right ventricle drives the progression of heart failure. European Journal of Heart Failure, 2017, 19, 1737-1737.	7.1	2
216	RELAXâ€AHF, BLASTâ€AHF, TRUEâ€AHF, and other important truths in acute heart failure research. European Journal of Heart Failure, 2017, 19, 1355-1357.	7.1	9

#	Article	IF	CITATIONS
217	Frequency and Prognostic Significance of Abnormal Liver Function Tests in Patients With Cardiogenic Shock. American Journal of Cardiology, 2017, 120, 1090-1097.	1.6	17
218	Bromocriptine for the treatment of peripartum cardiomyopathy: welcome on BOARD. European Heart Journal, 2017, 38, 2680-2682.	2.2	61
219	Mortality and acute exacerbation of COPD: a pilot study on the influence of myocardial injury. European Respiratory Journal, 2017, 49, 1700096.	6.7	7
220	Precipitating factors and 90â€day outcome of acute heart failure: a report from the intercontinental <scp>GREAT</scp> registry. European Journal of Heart Failure, 2017, 19, 201-208.	7.1	126
221	Clinical benefits of natriuretic peptides and galectin-3 are maintained in old dyspnoeic patients. Archives of Gerontology and Geriatrics, 2017, 68, 33-38.	3.0	4
222	Undetectable haptoglobin is associated with major adverse kidney events in critically ill burn patients. Critical Care, 2017, 21, 245.	5.8	11
223	Imbalanced Angiogenesis in Peripartum Cardiomyopathy ― Diagnostic Value of Placenta Growth Factor ―. Circulation Journal, 2017, 81, 1654-1661.	1.6	39
224	Plasma Levels of Soluble CD146 Reflect the Severity of Pulmonary Congestion Better Than Brain Natriuretic Peptide in Acute Coronary Syndrome. Annals of Laboratory Medicine, 2016, 36, 300-305.	2.5	27
225	European Society of Cardiology Heart Failure Longâ€Term Registry (<scp>ESCâ€HFâ€LT</scp>): 1â€year followâ€up outcomes and differences across regions. European Journal of Heart Failure, 2016, 18, 613-625.	7.1	538
226	Current real-life use of vasopressors and inotropes in cardiogenic shock - adrenaline use is associated with excess organ injury and mortality. Critical Care, 2016, 20, 208.	5.8	145
227	Signature of circulating <scp>microRNAs</scp> in patients with acute heart failure. European Journal of Heart Failure, 2016, 18, 414-423.	7.1	162
228	Enlarging Red Blood Cell Distribution Width During Hospitalization Identifies a Very High-Risk Subset of Acutely Decompensated Heart Failure Patients and Adds Valuable Prognostic Information on Top of Hemoconcentration. Medicine (United States), 2016, 95, e3307.	1.0	17
229	Heart failure diagnosis in acute conditions has high agreement with inpatient diagnosis. European Journal of Emergency Medicine, 2016, 23, 179-184.	1.1	9
230	Advanced heart failure: look right to prognosticate right!. European Journal of Heart Failure, 2016, 18, 573-575.	7.1	6
231	Understanding acute heart failure: pathophysiology and diagnosis. European Heart Journal Supplements, 2016, 18, G11-G18.	0.1	32
232	The role of levosimendan in acute heart failure complicating acute coronary syndrome: A review and expert consensus opinion. International Journal of Cardiology, 2016, 218, 150-157.	1.7	60
233	Role of cardiovascular biomarkers for the assessment of mitral stenosis and its complications. European Journal of Internal Medicine, 2016, 34, 58-62.	2.2	6
234	Prevalence and Prognosis of Hyperkalemia in Patients with Acute Myocardial Infarction. American Journal of Medicine, 2016, 129, 858-865.	1.5	35

#	Article	IF	CITATIONS
235	The value of novel invasive hemodynamic parameters added to the TIMI risk score for short-term prognosis assessment in patients with ST segment elevation myocardial infarction. International Journal of Cardiology, 2016, 214, 235-240.	1.7	6
236	Management of acute heart failure in elderly patients. Archives of Cardiovascular Diseases, 2016, 109, 422-430.	1.6	28
237	Natriuretic peptides in addition to Zwolle score to enhance safe and early discharge after acute myocardial infarction: A prospective observational cohort study. International Journal of Cardiology, 2016, 215, 527-531.	1.7	10
238	Low cardiac index and stroke volume on admission are associated with poor outcome in critically ill burn patients: a retrospective cohort study. Annals of Intensive Care, 2016, 6, 87.	4.6	28
239	Emergency management of severe hyperkalemia: Guideline for best practice and opportunities for the future. Pharmacological Research, 2016, 113, 585-591.	7.1	91
240	Effect of precipitating factors of acute heart failure on readmission and longâ€ŧerm mortality. ESC Heart Failure, 2016, 3, 115-121.	3.1	39
241	Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology. European Journal of Heart Failure, 2016, 18, 226-241.	7.1	455
242	The Model for Endâ€stage Liver Disease score inÂacute heart failure: hepatorenal dysfunction hides behind. European Journal of Heart Failure, 2016, 18, 1522-1523.	7.1	4
243	Body mass index in acute heart failure: association with clinical profile, therapeutic management and inâ€hospital outcome. European Journal of Heart Failure, 2016, 18, 298-305.	7.1	25
244	Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. European Journal of Heart Failure, 2016, 18, 1096-1105.	7.1	160
245	Similar hemodynamic decongestion with vasodilators and inotropes: systematic review, meta-analysis, and meta-regression of 35 studies on acute heart failure. Clinical Research in Cardiology, 2016, 105, 971-980.	3.3	39
246	Heart rate variability and cardiac baroreflex inhibition-derived index predicts pain perception in burn patients. Burns, 2016, 42, 1445-1454.	1.9	16
247	Natriuretic peptides, nitrite/nitrate and superoxide dismutase have additional value on top of the GRACE score in prediction of one-year mortality and rehospitalisation for heart failure in STEMI patients $\hat{a} \in$ ^o Multiple biomarkers prospective cohort study. International Journal of Cardiology, 2016, 211–96-104	1.7	28
248	Heterogeneity of the prognostic significance of B-type natriuretic peptide levels on admission in patients hospitalized for acute heart failure syndromes. European Journal of Internal Medicine, 2016, 31, 41-49.	2.2	5
249	Risk of oxalate nephropathy with the use of cyanide antidote hydroxocobalamin in critically ill burn patients. Intensive Care Medicine, 2016, 42, 1080-1081.	8.2	35
250	AHEAD score — Long-term risk classification in acute heart failure. International Journal of Cardiology, 2016, 202, 21-26.	1.7	59
251	Recommendations on preâ€hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. European Journal of Heart Failure. 2015. 17. 544-558.	7.1	315
252	Clinical presentation and outcome by age categories in acute heart failure: results from an international observational cohort. European Journal of Heart Failure, 2015, 17, 1114-1123.	7.1	49

#	Article	IF	CITATIONS
253	Post-ICU discharge and outcome: rationale and methods of the The French and euRopean Outcome reGistry in Intensive Care Units (FROG-ICU) observational study. BMC Anesthesiology, 2015, 15, 143.	1.8	35
254	Agents with vasodilator properties in acute heart failure: how to design successful trials. European Journal of Heart Failure, 2015, 17, 652-664.	7.1	24
255	Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine – short version. European Heart Iournal. 2015. 36. 1958-1966.	2.2	105
256	Understanding the differences among inotropes. Intensive Care Medicine, 2015, 41, 912-915.	8.2	32
257	Assessment of dyspnoea in the emergency department by numeric and visual scales: A pilot study. Anaesthesia, Critical Care & Pain Medicine, 2015, 34, 95-99.	1.4	8
258	Elevated Plasma B-Type Natriuretic Peptide Concentrations Directly InhibitÂCirculating Neprilysin Activity inÂHeartÂFailure. JACC: Heart Failure, 2015, 3, 629-636.	4.1	72
259	Soluble CD146, a new endothelial biomarker of acutely decompensated heart failure. International Journal of Cardiology, 2015, 199, 241-247.	1.7	44
260	Clinical picture and risk prediction of shortâ€ŧerm mortality in cardiogenic shock. European Journal of Heart Failure, 2015, 17, 501-509.	7.1	520
261	Experts' recommendations for the management of adult patients with cardiogenic shock. Annals of Intensive Care, 2015, 5, 52.	4.6	103
262	Neprilysin, cardiovascular, and Alzheimer's diseases: the therapeutic split?. European Heart Journal, 2015, 36, 902-905.	2.2	61
263	Neprilysin. JACC: Heart Failure, 2015, 3, 645-646.	4.1	6
264	Emotional impact of severe post-partum haemorrhage on women and their partners: an observational, case-matched, prospective, single-centre pilot study. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2015, 193, 140-143.	1.1	28
265	Evidence of Uncoupling between Renal Dysfunction and Injury in Cardiorenal Syndrome: Insights from the BIONICS Study. PLoS ONE, 2014, 9, e112313.	2.5	32
266	Consensus on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care Medicine. Intensive Care Medicine, 2014, 40, 1795-1815.	8.2	1,240
267	When Cardiac Failure, Kidney Dysfunction, and Kidney Injury Intersect in Acute Conditions. Critical Care Medicine, 2014, 42, 2109-2117.	0.9	54
268	Post-translational modifications enhance NT-proBNP and BNP production in acute decompensated heart failure. European Heart Journal, 2014, 35, 3434-3441.	2.2	90
269	Diagnosis and treatment of iron deficiency in patients with heart failure: Expert position paper from French cardiologists. Archives of Cardiovascular Diseases, 2014, 107, 563-571.	1.6	27
270	Iron deficiency: an emerging therapeutic target in heart failure. Heart, 2014, 100, 1414-1420.	2.9	95

#	Article	IF	CITATIONS
271	Predicting the Risk of Venous Thromboembolism in Patients Hospitalized With Heart Failure. Circulation, 2014, 130, 410-418.	1.6	53
272	Heart â€~omics' in AGEing (HOMAGE): design, research objectives and characteristics of the common database. Journal of Biomedical Research, 2014, 28, 349.	1.6	24
273	Implantable Cardiac Devices and the Acute Care Management of Decompensated Heart Failure. Current Emergency and Hospital Medicine Reports, 2013, 1, 105-111.	1.5	2
274	Gender-related differences in patients with acute heart failure: Management and predictors of in-hospital mortality. International Journal of Cardiology, 2013, 168, 185-189.	1.7	36
275	Association Between Elevated Blood Glucose and Outcome in Acute Heart Failure. Journal of the American College of Cardiology, 2013, 61, 820-829.	2.8	111
276	Comparison of the diagnostic and prognostic values of B-type and atrial-type natriuretic peptides in acute heart failure. International Journal of Cardiology, 2013, 168, 3404-3411.	1.7	64
277	Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: The Multinational Observational Cohort on Acute Heart Failure (MOCA) study. International Journal of Cardiology, 2013, 168, 2186-2194.	1.7	207
278	Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failureâ€. European Heart Journal, 2013, 34, 57-67.	2.2	128
279	Liver function abnormalities, clinical profile, and outcome in acute decompensated heart failure. European Heart Journal, 2013, 34, 742-749.	2.2	234
280	The Effectiveness of Inodilators in Reducing Short Term Mortality among Patient with Severe Cardiogenic Shock: A Propensity-Based Analysis. PLoS ONE, 2013, 8, e71659.	2.5	44
281	Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes. European Journal of Heart Failure, 2012, 14, 1056-1066.	7.1	105
282	Unbiased plasma proteomics for novel diagnostic biomarkers in cardiovascular disease: identification of quiescin Q6 as a candidate biomarker of acutely decompensated heart failure. European Heart Journal, 2012, 33, 2317-2324.	2.2	70
283	Levosimendan: Molecular mechanisms and clinical implications. International Journal of Cardiology, 2012, 159, 82-87.	1.7	256
284	Impact of diuretic dosing on mortality in acute heart failure using a propensityâ€matched analysis. European Journal of Heart Failure, 2011, 13, 1244-1252.	7.1	52
285	Beneficial association of β-blocker therapy on recovery from severe acute heart failure treatment: Data from the Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support trial*. Critical Care Medicine, 2011, 39, 940-944.	0.9	49
286	Short-term survival by treatment among patients hospitalized with acute heart failure: the global ALARM-HF registry using propensity scoring methods. Intensive Care Medicine, 2011, 37, 290-301.	8.2	196
287	Reply to Ferrer et al.: propensity scores in intensive care literature. Intensive Care Medicine, 2011, 37, 883-883.	8.2	0
288	Propensity scores in intensive care and anaesthesiology literature: a systematic review. Intensive Care Medicine, 2010, 36, 1993-2003.	8.2	105

#	Article	IF	CITATIONS
289	The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study. European Heart Journal, 2010, 31, 832-841.	2.2	159
290	Acute pulmonary oedema: clinical characteristics, prognostic factors, and inâ€hospital management. European Journal of Heart Failure, 2010, 12, 1193-1202.	7.1	45
291	Congestion and Cardiorenal Syndromes. Contributions To Nephrology, 2010, 165, 140-144.	1.1	11
292	Clinical review: Practical recommendations on the management of perioperative heart failure in cardiac surgery. Critical Care, 2010, 14, 201.	5.8	158
293	Levosimendan vs. dobutamine: outcomes for acute heart failure patients on βâ€blockers in SURVIVEâ€. European Journal of Heart Failure, 2009, 11, 304-311.	7.1	144
294	Midregional pro-Adrenomedullin in addition to b-type natriuretic peptides in the risk stratification of patients with acute dyspnea: an observational study. Critical Care, 2009, 13, R122.	5.8	48
295	Lowered B-Type Natriuretic Peptide in Response to Levosimendan or Dobutamine Treatment Is Associated With Improved Survival in Patients With Severe Acutely Decompensated Heart Failure. Journal of the American College of Cardiology, 2009, 53, 2343-2348.	2.8	107
296	Current ESC/ESICM and ACCF/AHA guidelines for the diagnosis and management of acute heart failure in adultsare there differences?. , 2009, 119, 569-73.		5
297	Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008: The Fask Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). European Heart Journal,	2.2	2,656
298	Practical recommendations for prehospital and early in-hospital management of patients presenting with acute heart failure syndromes. Critical Care Medicine, 2008, 36, S129-S139.	0.9	240
299	Levosimendan vs Dobutamine for Patients With Acute Decompensated Heart Failure. JAMA - Journal of the American Medical Association, 2007, 297, 1883.	7.4	834
300	Clinical profile, contemporary management and one-year mortality in patients with severe acute heart failure syndromes: The EFICA studya †. European Journal of Heart Failure, 2006, 8, 697-705.	7.1	286
301	Randomized Clinical Trials with Levosimendan. American Journal of Cardiology, 2005, 96, 74-79.	1.6	31
302	Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: The Task Force on Acute Heart Failure of the European Society of Cardiology. European Heart Journal, 2005, 26, 384-416.	2.2	1,114
303	Acute right ventricular failure—from pathophysiology to new treatments. Intensive Care Medicine, 2004, 30, 185-196.	8.2	193
304	Cardiac contractile impairment associated with increased phosphorylation of troponin I in endotoxemic rats. FASEB Journal, 2001, 15, 294-296.	0.5	168
305	Case of Triple Endocarditis Caused by <i>Rothia dentocariosa</i> and Results of a Survey in France. Journal of Clinical Microbiology, 1998, 36, 309-310.	3.9	21